Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma (Nasdaq: OKYO) reported that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The company is a clinical-stage biopharmaceutical developer of investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares listed on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients to assess a single-dose regimen.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share.
OKYO’s ordinary shares trade on the Nasdaq Capital Market. According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients in a single-dose regimen study.
OKYO Pharma (Nasdaq: OKYO) reported that Chief Development Officer and Director Gary S. Jacob, PhD, purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holding to 112,420 ordinary shares.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share. OKYO is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
OKYO Pharma (Nasdaq: OKYO) will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026 at 12:30 PM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will present virtually. OKYO is developing urcosimod for neuropathic corneal pain and plans a global Phase 3 trial.
OKYO Pharma (Nasdaq: OKYO) reported that Chairman Gabriele Cerrone, via Panetta Partners, purchased 25,000 ordinary shares at $1.40 per share. According to OKYO Pharma, this increases his total holding to 10,851,416 shares, representing 20.51% of the company’s issued share capital.
The clinical-stage biopharmaceutical company focuses on therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. OKYO plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) filed its Annual Report on Form 20-F for the year ended March 31, 2026, and reported a strengthened cash position supporting its late-stage development plans. According to the company, it raised approximately $25 million during the fiscal year, including a February 2026 public offering generating about $22 million in gross proceeds.
OKYO reported cash and cash equivalents of roughly $20.6 million at March 31, 2026, which it expects will fully fund the FDA-agreed global Phase 3 NEPTUNE pivotal trial of urcosimod in neuropathic corneal pain. NEPTUNE, planned to start in the second half of 2026, will enroll about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen and is designed as a potential registrational study following positive FDA Type D feedback.
OKYO Pharma (Nasdaq: OKYO) reported positive FDA Type D feedback supporting advancement of urcosimod into NEPTUNE, a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). The FDA aligned on a single-dose study design and a potential single-trial registration pathway, subject to successful outcomes and continued review.
The NEPTUNE trial plans to enroll about 111 subjects, randomized 2:1 to 0.05% urcosimod versus placebo in the United States and Europe. OKYO intends to seek Breakthrough Therapy Designation to further accelerate development, building on urcosimod’s existing Fast Track status and open IND for NCP.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharma focused on neuropathic corneal pain and anterior segment eye diseases, will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium.
The virtual event is scheduled for Thursday, July 9, 2026 at 8:30 AM ET, featuring CEO Robert J. Dempsey and CMO Flavio Mantelli, moderated by Biren Amin of Piper Sandler.
OKYO (Nasdaq: OKYO), a clinical-stage biopharma company focused on neuropathic corneal pain and inflammatory eye diseases, appointed Marta Sacchetti, MD, PhD to its Scientific Advisory Board.
She is an Associate Professor of Ophthalmology in Rome with prior global clinical development leadership in ophthalmology and neurotrophins. OKYO’s lead candidate urcosimod holds an IND and FDA Fast Track designation for neuropathic corneal pain.